Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, USA.
Bridges to Development, Seattle, Washington, USA.
Int Health. 2020 Dec 22;13(Suppl 1):S60-S64. doi: 10.1093/inthealth/ihaa046.
The Global Programme to Eliminate Lymphatic Filariasis (LF) is using mass drug administration (MDA) of antifilarial medications to treat filarial infections, prevent disease and interrupt transmission. Almost 500 million people receive these medications each year. Clinical trials have recently shown that a single dose of a triple-drug combination comprised of ivermectin, diethylcarbamazine and albendazole (IDA) is dramatically superior to widely used two-drug combinations for clearing larval filarial parasites from the blood of infected persons. A large multicenter community study showed that IDA was well-tolerated when it was provided as MDA. IDA was rapidly advanced from clinical trial to policy and implementation; it has the potential to accelerate LF elimination in many endemic countries.
全球消灭淋巴丝虫病规划（LF）正在使用抗丝虫药物进行大规模药物治疗（MDA），以治疗丝虫感染、预防疾病和阻断传播。每年有近 5 亿人接受这些药物治疗。最近的临床试验表明，伊维菌素、乙胺嗪和阿苯达唑（IDA）组成的三药组合一剂即可显著优于广泛使用的二药组合，从受感染者的血液中清除幼虫期丝虫寄生虫。一项大型多中心社区研究表明，当 MDA 提供时，IDA 具有良好的耐受性。IDA 已迅速从临床试验推进到政策和实施阶段；它有可能加速许多流行国家的 LF 消除。
